Navigation Links
Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer

LONDON, June 19, 2012 /PRNewswire/ -- The Foundation for Research on the Nervous System, Replikins Ltd., and Bioradar UK Ltd. today announced that over 100 new synthetic Replikins vaccines for infectious diseases and cancer are now available as a result of the discovery by scientists Drs. Samuel and Elenore Bogoch of the evolution of the genomic Replikins over time -- from ocean archaea to human cancer. A book on this subject will be released in September 2012.

Peak Gene Replikin Count:

Drs. Bogoch have determined that the highest peak gene Replikin Counts are six-fold greater in brain cancer than the Counts in ocean archaea and viruses. The ability to specify certain increasing genomic sequences related to lethality has permitted new synthetic vaccines for organisms such as Taura Syndrome Virus, infectious salmon anemia virus, universal influenza virus strains, highly lethal drug-resistant tuberculosis, and malaria, and cancers of histological type with the highest five-year mortality rates for which vaccines have not previously been available.

Because these Replikins genomic sequences have been shown to provide 1-2 years advance notice of outbreaks, effective synthetic vaccines have been manufactured by the Companies in seven days, providing time for adequate testing, and can be delivered in freeze-dried form in literally limitless quantities.


Accounts of some of the work on individual products have been published 1) in eight papers in Nature Precedings 2011-2012 (; 2) on the companies' website (, which contains over 40 news announcements from 2006-present; and 3) in patent publications from 2002-present.

Contact: Dr. S. Bogoch, 646-320-5910

This press release was issued through eReleases® Press Release Distribution. For more information, visit

SOURCE Replikins Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Australian Discovered Biomarkers Map Path to New Blood Test for Bowel Cancer
2. Novel method to make nanomaterials discovered
3. Dual-acting class of antimalarial compounds discovered with potential to prevent and treat malaria
4. Evolution Issue of the Month 2. Natural Selection--Not the Best Idea Anyone Ever Had
5. Martha Stewart Reveals the Secret Behind her Radiant Skin is Revolutionary Anti-aging BIOEFFECT EGF SERUM
6. New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
7. Luminex Corporation Receives CE Mark for Revolutionary Newborn Screening Platform
8. PTV Interview Exclusive: Revolutionary GSK and J&J Participation in New Index Ventures Fund
9. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
10. Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing
11. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... on behalf of the Toronto Stock Exchange, confirms that ... are no corporate developments that would cause the recent ... --> --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical ...
Breaking Biology Technology:
(Date:10/26/2015)... October 26, 2015 ... adds Biometrics Market Shares, ... as well as Emerging Biometrics Technologies: ... to its collection of IT and ... . --> ...
(Date:10/23/2015)... , Oct. 23, 2015 Research and ... the "Global Voice Recognition Biometrics Market 2015-2019" ... --> The global voice recognition biometrics ... 2014-2019. --> --> ... has been prepared based on an in-depth market analysis ...
(Date:10/22/2015)... SYNA ), a leading developer of human interface solutions, today reported ... --> --> Net revenue for ... comparable quarter last year to $470.0 million. Net income for the ... diluted share. --> --> ... 39 percent over the prior year period to $56.9 million, or ...
Breaking Biology News(10 mins):